Apollomics (APLM) AI Stock Analysis

• Market Cap: $15.28M
• Dividend Yield: N/A
• Average Volume (3M): 72.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 80.54%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -16.91
• Shares Outstanding: 1,103,348
• 10 Day Avg. Volume: 95,090
• 30 Day Avg. Volume: 72,653
• PEG Ratio: <0.01
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 45.62
• P/FCF Ratio: -0.31
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 9.86
• Enterprise Value/Gross Profit: 9.86
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $11.50 ▼(-18.90% Downside)

Apollomics' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. The technical analysis further indicates bearish momentum, while the negative P/E ratio highlights valuation concerns. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

How the Company Makes Money

Apollomics generates revenue through several key streams, including partnerships with pharmaceutical companies for co-development agreements and licensing deals for its drug candidates. The company may also receive milestone payments as its products advance through clinical trials and regulatory approvals. Additionally, Apollomics could earn royalties on sales from any commercialized drugs that result from its research efforts. Significant collaborations with larger pharmaceutical firms enhance its financial stability and provide access to broader markets, thereby contributing to its overall earnings potential.

Apollomics Financial Statement Overview

Summary

Apollomics faces significant financial challenges, characterized by declining revenues, persistent losses, and negative cash flows. While leverage is relatively low, the company struggles with profitability and cash management. Strategic improvements are necessary to stabilize and enhance financial performance.

Income Statement

Apollomics has experienced significant revenue volatility, with a dramatic decline in revenue in the most recent year. The company has consistently reported negative net profit margins and EBIT margins, indicating ongoing profitability challenges. Despite a positive gross profit margin, the overall financial performance is weak due to substantial operating losses.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, which suggests manageable leverage. However, the negative return on equity and fluctuating equity levels highlight ongoing financial instability. The equity ratio has improved but remains a concern due to historical negative equity.

Cash Flow

Apollomics has consistently reported negative operating and free cash flows, reflecting cash management challenges. The free cash flow to net income ratio is stable, but the negative growth in free cash flow indicates potential liquidity issues. The company needs to improve cash flow generation to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	198.00K	821.00K	323.00K	2.00K	1.84M
Gross Profit	198.00K	821.00K	323.00K	2.00K	1.84M
EBITDA	-41.05M	-53.45M	-43.88M	-50.12M	-40.51M
Net Income	-53.86M	-172.60M	-240.81M	-94.80M	-74.82M
Balance Sheet
Total Assets	13.10M	55.39M	76.47M	123.44M	169.94M
Cash, Cash Equivalents and Short-Term Investments	9.77M	37.82M	54.61M	94.48M	154.39M
Total Debt	966.00K	4.66M	991.00K	1.04M	1.51M
Total Liabilities	8.23M	14.15M	524.60M	336.30M	297.87M
Stockholders Equity	4.86M	41.23M	-448.12M	-212.86M	-127.93M
Cash Flow
Free Cash Flow	-28.77M	-43.22M	-43.19M	-43.36M	-35.82M
Operating Cash Flow	-28.74M	-43.21M	-42.82M	-43.31M	-35.68M
Investing Cash Flow	5.98M	21.36M	29.05M	-38.95M	2.33M
Financing Cash Flow	468.00K	21.23M	-294.00K	-1.64M	125.51M

Apollomics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.18
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Neutral. The current price of 14.18 is below the 20-day moving average (MA) of 20.68, below the 50-day MA of 16.41, and above the 200-day MA of 9.05, indicating a neutral trend. The MACD of -1.50 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of 20.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APLM.

Apollomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XCUR	48 Neutral	$26.85M	―	-150.50%	―	-100.00%	64.16%
APLM	41 Neutral	$15.28M	-0.25	―	―	―	80.54%
GDTC	41 Neutral	$22.06M	―	-42.29%	―	―	-21.99%
CLGN	38 Underperform	$28.23M	-1.97	-78.25%	―	248.62%	26.22%
HIND	37 Underperform	$31.09M	―	-101.49%	―	-19.81%	93.32%

Apollomics Corporate Events

Apollomics Inc.’s APL-101 Study: A Potential Game-Changer in Cancer Treatment

Apollomics Inc. is conducting a Phase 1/2 study titled ‘Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors’. The study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of APL-101 in treating various cancers, including non-small cell lung cancer (NSCLC) with specific genetic mutations. This research is significant as it targets MET gene alterations, which are implicated in cancer progression.